Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01-Reference-Cited by-同舟云学术

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01

Published:2011-11-18 Issue:2 Volume:132 Page:589-600
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Im Seock-Ah,Lee Keun Seok,Ro Jungsil,Lee Eun Sook,Kwon Youngmee,Ahn Jin-Hee,Ahn Jin Seok,Kim Jee Hyun,Kang Han Sung,Shin Kyung Hwan,Noh Dong-Young,Park In-Ae,Kim Sung-Bae,Im Young Hyuck,Ha Sung Whan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-011-1852-0.pdf

Reference46 articles.

1. Gusterson BA, Gelber RD, Goldhirsch A et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049–1056

2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

3. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

4. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

5. Campone M, Roche H, Kerbrat P et al (2005) Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol 16:1343–1351

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncoproteomics by 3D MALDI with MRI-PET Imaging in Cancer;Pharmacoproteomics;2024

2. Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence;Frontiers in Endocrinology;2023-10-12

3. Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report;Clinical Medicine Insights: Case Reports;2023-01

4. Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis;BJS Open;2022-05-02

5. Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data;Therapeutic Advances in Drug Safety;2022-01